DEXA Scan Body Composition Results: How to Read Every Metric

Introduction: Your DEXA Results Are More Than a Number

A patient receives their DEXA report and stares at a dense grid of figures: body fat percentage, VAT mass, ALMI, T-scores, regional lean mass by limb. Most people zero in on one line, the body fat percentage, and quietly ignore the rest. That is a mistake, because the real clinical value of a DEXA scan lives in the metrics almost no one knows how to read.

This is not an explainer on what a DEXA scan is. It is an interpretation guide for people who already understand the basics and want to extract genuine meaning from their results. DEXA (Dual-Energy X-ray Absorptiometry) is widely recognized as the gold standard for body composition measurement, using low-intensity X-rays to separate lean mass, fat mass, and bone mass in a three-compartment model.

This article walks through five major metric categories: body fat percentage and fat distribution, visceral adipose tissue (VAT), appendicular lean mass index (ALMI), regional lean mass symmetry, and bone mineral density (BMD). For each category, the goal is not simply to explain what the number means, but to clarify what it means for health, risk, and next steps.

How a DEXA Scan Generates Its Data

A DEXA scanner emits two low-energy X-ray beams at different frequencies. Bone, lean tissue, and fat each attenuate those beams differently, which allows software to precisely separate all three compartments. A full-body scan takes roughly 7 to 12 minutes, and radiation exposure is less than two days of natural background radiation, far below a standard chest X-ray.

The three-compartment model (bone mineral content, lean soft tissue mass, and fat mass) is what makes DEXA more precise than the two-compartment models used by bioelectrical impedance analysis (BIA) devices like InBody. According to a critical overview published in PMC, DEXA is the current reference method for body composition assessment. Measurement stability is verified at better than 1% over time when standardized protocols are followed, making it highly reliable for longitudinal tracking.

One important caveat: results can vary slightly between GE Lunar and Hologic systems due to different software algorithms, which matters when comparing scans from different facilities over time.

Body Fat Percentage: Reading Beyond the Single Number

DEXA measures body fat percentage with ±1 to 2% accuracy, compared to ±3 to 5% for BIA devices and home smart scales. A landmark 2025 study by Looney et al. of 1,000 healthy adults found that the InBody 770 underestimated fat mass by an average of 3.7 kg in men and 1.9 kg in women, and underestimated body fat percentage by roughly 4.2 percentage points in men compared to DEXA.

A single body fat number is only a starting point. Its clinical value comes from where that fat sits and how it is distributed. This is why total fat mass is often less useful than the fat mass index (FMI), which normalizes fat mass to height squared for meaningful comparison across body sizes.

This distinction also explains why BMI falls short. Research shows up to 29 million U.S. adults with a “healthy” BMI still carry metabolic risk factors typical of obesity, a pattern called TOFI (Thin Outside, Fat Inside). A commission led by The Lancet Diabetes and Endocrinology has argued that BMI is insufficient as an individual-level health measure. BMI inflates for muscular athletes and conceals danger in TOFI individuals. DEXA catches both failure modes.

Subcutaneous vs. Visceral Fat: Why Location Is Everything

Subcutaneous fat sits under the skin and is metabolically quieter. Visceral adipose tissue (VAT) wraps around internal organs and is highly active. VAT releases inflammatory cytokines and free fatty acids directly into the portal vein, impairing hepatic insulin signaling and driving insulin resistance, the precursor to type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.

VAT correlates with cardiometabolic markers (blood pressure, triglycerides, HDL, insulin, and HOMA-IR) even before traditional risk factors turn abnormal. A 2019 consensus statement in Nature Reviews Endocrinology concluded that visceral adiposity, not overall weight, is the dominant driver of cardiometabolic risk in obesity. Two people with identical body fat percentages can carry dramatically different risk depending on VAT.

Visceral Adipose Tissue (VAT): The Metric That Changes Everything

DEXA estimates VAT using the android (abdominal) region, with software modeling the volume and mass of fat in the visceral compartment, validated against CT. A 2025 study in the British Journal of Radiology found DEXA closely matched CT results for fat and lean mass in the limbs and abdomen across 103 adults scanned the same day.

Clinical thresholds are commonly cited as follows: a VAT area of 100 cm² or more signals elevated risk, and 160 cm² or more indicates high risk, interpreted alongside age, sex, and BMI. In practical terms, someone with a VAT area of 120 cm² and a normal BMI of 23 carries meaningfully elevated risk that their scale and BMI would completely miss.

VAT is reported as a volume (cm³ or liters), a mass (grams or kilograms), and sometimes an estimated area (cm²). It is arguably the single most important output of the scan because it is the metric most likely to change a person’s clinical risk classification. One limitation: DEXA VAT estimates are less accurate in individuals with very high body mass, where CT or MRI remains the reference standard.

Appendicular Lean Mass Index (ALMI): The Sarcopenia Screen Hidden in Your Results

ALMI is the sum of lean mass in both arms and both legs divided by height in meters squared, expressed in kg/m². Appendicular lean mass is used instead of total lean mass because trunk lean mass includes organ mass and is a poorer proxy for functional skeletal muscle.

Clinical cut-points place ALMI below 7.0 kg/m² in men and 5.5 kg/m² in women as screening thresholds for low muscle mass consistent with sarcopenia. Sarcopenia, the age-related loss of muscle mass and function, affects an estimated 10% of adults over 50 and accelerates sharply after 60, raising risk of falls, fractures, and loss of independence.

DEXA-derived ALMI is the clinical standard for diagnosing sarcopenia before it becomes a functional problem. The International Society for Clinical Densitometry’s dedicated DXA Body Composition Analysis course in May 2026 reflects this growing clinical adoption. A low-normal or below-normal ALMI is a direct signal to prioritize resistance training and protein intake, with targets that follow-up scans can validate.

Regional Lean Mass: Reading the Symmetry Data

DEXA breaks lean tissue into five regions: right arm, left arm, trunk, right leg, and left leg. This map is something no scale, BMI calculation, or BIA device can produce. Each region shows lean mass in grams or kilograms, often with a percentage comparison between paired limbs.

Minor asymmetry is normal (a dominant-arm advantage of 5 to 10% is typical), but larger differences, especially in the legs, can indicate compensatory movement, prior injury, or neurological asymmetry. A leg lean mass asymmetry greater than 10 to 15% has been associated with elevated injury risk and is used by sports medicine clinicians to guide corrections. Regional data is also used to track recovery after orthopedic surgery, such as quantifying quad atrophy after ACL reconstruction. Research on NCAA Division I athletes confirms that lean mass distribution varies by sport and sex.

Lean Mass Asymmetry and Injury Risk: A Closer Look

Consider a concrete example: the right leg shows 9.8 kg of lean mass and the left shows 8.2 kg. That is a 16% asymmetry that warrants attention regardless of body fat percentage. Asymmetries develop silently, as a limb loses relative muscle through disuse or pain avoidance while the person feels functionally normal. DEXA provides exact numbers, enabling targeted corrections verified on follow-up scans rather than estimated through circumference tape.

Bone Mineral Density (BMD): T-Scores, Z-Scores, and Fracture Risk

BMD is reported in grams per square centimeter for specific sites (lumbar spine L1 to L4, femoral neck, and total hip), then converted into standardized scores.

• T-score: standard deviations above or below a healthy young adult of the same sex. Normal is ≥ -1.0; osteopenia falls between -1.0 and -2.5; osteoporosis is ≤ -2.5.
• Z-score: standard deviations relative to same-age, same-sex, same-ethnicity peers, more relevant for younger adults and children.

Fracture risk roughly doubles per standard-deviation drop, so a T-score of -2.5 carries approximately four times the risk of -0.5. Osteopenia and early osteoporosis are largely asymptomatic, and DEXA is the only non-invasive tool that detects bone loss before a fracture occurs. The femoral neck T-score is especially predictive of hip fracture, while lumbar spine BMD responds faster to intervention. Raw scores must be read alongside age, sex, menopausal status, and medication use.

The “Skinny Fat” Pattern: What DEXA Catches That BMI and InBody Miss

TOFI individuals have a BMI below 25 but carry disproportionate visceral fat and low lean mass. BMI cannot distinguish fat from muscle from bone, so a lean-looking person with low muscle and high VAT reads as “normal.” BIA devices estimate total fat from impedance but cannot directly measure visceral fat, and are subject to hydration confounds and systematic underestimation. The Looney et al. finding of a 3.7 kg fat underestimation in men means InBody may label a TOFI individual as acceptable while DEXA reveals dangerous VAT levels.

On a DEXA report, the TOFI pattern appears as normal or low total body fat percentage combined with elevated VAT, low ALMI, and low limb lean mass: a story the scale never tells.

DEXA for GLP-1 Medication Users: Why Body Composition Monitoring Is Essential

Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) produce significant weight loss, but scale weight cannot separate fat loss from muscle loss. DEXA sub-studies of the STEP 1 and SURMOUNT-1 trials confirmed that roughly a quarter to nearly half of weight lost can be lean mass rather than fat.

Losing lean mass worsens sarcopenia risk, lowers resting metabolic rate, and undermines long-term weight maintenance. A baseline scan before starting therapy, followed by scans every 3 to 6 months, tracks the ratio of fat to lean loss so protein intake and resistance training can be adjusted accordingly. ALMI is the key metric to monitor; a declining ALMI signals the need for immediate intervention. For GLP-1 users, DEXA is a medically necessary monitoring tool, not a luxury add-on.

Understanding DEXA’s Limitations: What the Report Cannot Tell You

• Hydration: fluid intake of 0.8 to 2.4 liters can inflate lean mass estimates, especially in the trunk, making standardized pre-scan protocols essential.
• VAT at extremes: estimates lose precision above a BMI of 40, where CT or MRI is preferred.
• Beam hardening: in very large individuals, this artifact can distort tissue density readings.
• Cross-machine comparability: GE Lunar and Hologic results are not directly interchangeable; the same machine should be used for longitudinal tracking.
• Lean mass is not pure muscle: it includes water, connective tissue, organ mass, and glycogen, which is why ALMI is a better muscle proxy than total lean mass.

A provider that explains these limitations is more credible than one that oversells the technology.

How to Use DEXA Results: Translating Data Into Action

• Elevated VAT: prioritize 150 or more minutes weekly of moderate cardio (which carries the strongest evidence for visceral fat reduction), reduce ultra-processed foods, and consider follow-up metabolic testing (fasting insulin, HOMA-IR, lipid panel).
• Low ALMI: target 1.6 to 2.2 g/kg body weight of protein daily, perform resistance training 2 to 4 times weekly, and rescan in 3 to 6 months.
• Lean mass asymmetry: work with a physical therapist or coach to correct compensatory movement patterns, then verify progress with follow-up scans.
• Low BMD: discuss pharmacological options with a physician alongside weight-bearing exercise, calcium, vitamin D, and protein; rescan every 1 to 2 years.
• TOFI pattern: target VAT reduction and lean mass preservation, not simply lower scale weight.

A single scan is a snapshot; serial scans reveal whether interventions are working. The clinical team at Belmar Cardiopulmonary Diagnostic Center can help patients contextualize these results within their broader health picture and build a personalized action plan.

Conclusion: Your DEXA Report Is a Clinical Document

A DEXA report contains five distinct metric categories, each carrying independent clinical weight that BMI and scale weight cannot capture. VAT is the cardiometabolic marker that changes risk classification; ALMI is the early sarcopenia screen embedded in the results; regional lean mass reveals injury risk; BMD T-scores quantify fracture risk; and the TOFI pattern is invisible to every tool except DEXA.

Reading these metrics correctly requires context: age, sex, medical history, medications, and goals all shape what a number means. As clinical standards shift toward body composition-first assessment, driven by the limits of BMI, the rise of GLP-1 therapies, and growing awareness of sarcopenia, DEXA is becoming a foundational health screen. Its full value is realized only when credentialed professionals connect the data to a plan.

Ready to See What the Numbers Actually Mean?

For those ready to move beyond guesswork, scheduling a DEXA body composition scan at Belmar Cardiopulmonary Diagnostic Center in Bellevue, WA is a practical next step. Every scan is performed, overseen, and interpreted by licensed, credentialed staff and board-certified physicians, so patients leave with clinical context rather than just a printout.

Flexible scheduling, including weekend availability, makes it easier to book around a busy schedule. To get started, contact BCDC at 206-730-9364 or hello@belmarcardio.org, or use the online appointment form to reserve a visit.